On Monday shares of Cara Therapeutics Inc. (NASDAQ:CARA) closed at $10.05. On May 12, Cara Therapeutics, Inc. (Nasdaq:CARA announced financial results for the first quarter ended March 31, 2015. Net loss was $4.7 million, or $0.21 per basic and diluted share, for the first quarter of 2015, compared to net loss of $3.4 million, or $0.22 per basic and diluted share for the same period of 2014.
Cypress Semiconductor Corporation (NASDAQ:CY) in last trading activity moved up 2.45% to close at $13.39. Company weekly performance is 6.02% while its quarterly performance stands at -7.94%. Cypress Semiconductor Corporation (NASDAQ:CY) is -17.01% away from its 52 week high. On May 14, Cypress Semiconductor Corporation (NASDAQ:CY) said that it has approached chipmaker Integrated Silicon Solution Inc with a $627.3 million takeover offer it hopes will trump the $611.4 million deal that ISSI already inked with a Summitview Capital-led Chinese consortium of investors.
On last trading day ConAgra Foods, Inc. (NYSE:CAG) moved up 0.08% to close at $38.52. Its volatility for the week is 1.39% while volatility for the month is 1.33%. CAG’s sales growth for past 5 years was 7.50% and its EPS growth for past 5 years was -12.30%. ConAgra Foods, Inc. (NYSE:CAG) monthly performance is 3.97%. ConAgra Foods said it will close one of its cookie plants in Ripon. WLUK-TV reports about 300 full-time employees will be laid off. WLUK reported workers were being told Monday, with layoffs starting in September and completed by December. ConAgra said the closing covers its west plant that makes soft-bake and so-called enrobed cookies. The company’s east plant, which makes wafer cookies and employs about 80 people, isn’t affected.
On Monday shares of Eli Lilly and Company (NYSE:LLY) closed at $72.94. Company’s sales growth for last 5 years was -2.10% and EPS growth for next 5 years is recorded as 4.63%. Eli Lilly and Company (NYSE:LLY) and Sanford-Burnham Medical Research Institute announced that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit medical research institute, will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren’s Syndrome, inflammatory bowel disease and other autoimmune disorders.
On last trading day Credit Acceptance Corp. (NASDAQ:CACC) fell -0.32% to close at $229.50. Its volatility for the week is 2.59% while volatility for the month is 2.98%. CACC’s sales growth for past 5 years was 13.70% and its EPS growth for past 5 years was 20.90%. Credit Acceptance Corp. (NASDAQ:CACC) monthly performance is 16.37%. Credit Suisse reaffirmed their neutral rating on shares of Credit Acceptance Corp. (NASDAQ:CACC) in a research note issued to investors on Thursday. The firm currently has a $220.00 price target on the stock, up from their previous price target of $200.00.